Hidden Drug Ingredients in Supplements: What the Boner Bears Recall Teaches Us

Last updated: 2026-03-05

On February 25, 2026, McKinney, Texas-based Lockout Supplements initiated a voluntary nationwide recall of all lots of Boner Bears Chocolate Syrup after FDA testing confirmed the product contained sildenafil — a prescription-only drug — that was not declared anywhere on the product label. The recall is listed on the FDA's official safety alerts and recalls database.

But here is the lesson that matters far more than the recall itself: undeclared drug ingredients in dietary supplements are one of the most preventable — and most prosecuted — violations in FDA's enforcement portfolio. If you manufacture, distribute, or market dietary supplements, especially those positioned for sexual enhancement, energy, or weight loss, this recall is a direct signal that your own supply chain and testing protocols need scrutiny right now.

At Certify Consulting, I have guided 200+ supplement and food companies through FDA inspections and compliance audits. The pattern in cases like this is almost always the same: a failure somewhere between raw material qualification and final product testing. Let me walk you through exactly what went wrong, what regulations apply, and what you need to do to make sure your company never appears on the FDA's recall list for the same reason.

What Happened: The Boner Bears Chocolate Syrup Recall

According to the FDA's recall notice, Lockout Supplements voluntarily recalled all lots of Boner Bears Chocolate Syrup due to the presence of sildenafil — the active pharmaceutical ingredient in Viagra® — which was not listed on the product label. The recall was classified as a significant public health concern because sildenafil can interact dangerously with nitrate-based medications commonly prescribed for heart disease, potentially causing a severe and life-threatening drop in blood pressure.

The product was marketed and sold as a dietary supplement. Under federal law, a dietary supplement cannot legally contain a pharmaceutical drug ingredient. The moment sildenafil was detected, the product crossed a bright legal line: it was no longer a supplement — it was an adulterated and misbranded drug under 21 U.S.C. § 331.

Citation hook: The FDA has authority under 21 U.S.C. § 342(a)(2)(C) to deem a dietary supplement adulterated if it contains a drug ingredient that renders the product unsafe, regardless of whether the manufacturer was aware of the contamination.

The Regulatory Framework: Why This Is a Federal Violation

Understanding the specific regulations involved is critical for any compliance team. This is not a gray area.

21 U.S.C. § 331 — Prohibited Acts

Section 331 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) prohibits the introduction of adulterated or misbranded food or drugs into interstate commerce. A supplement containing an undeclared prescription drug ingredient violates both prongs simultaneously.

21 CFR Part 111 — Current Good Manufacturing Practice (cGMP) for Dietary Supplements

This is where most enforcement leverage lives. Specifically:

21 CFR § 111.75 requires that you establish product specifications and verify that finished batch specifications are met before releasing product for distribution.
21 CFR § 111.70(b) requires component specifications that ensure no component contains an adulterant.
21 CFR § 111.320 requires laboratory testing of finished product to confirm identity and purity.
21 CFR § 111.260 requires a quality control review of every batch before release.

When sildenafil appears in a finished supplement, it is almost certain that at least one — and usually several — of these requirements were not properly implemented.

21 CFR Part 101 — Food Labeling

Beyond adulteration, failure to declare an ingredient on the label violates 21 CFR § 101.4, which requires all ingredients to be listed by common or usual name. An undeclared active drug ingredient is a textbook misbranding violation under 21 U.S.C. § 343(a).

FD&C Act § 403(a)(1) — Misbranding

A product is misbranded if its labeling is false or misleading in any particular. A label that does not disclose sildenafil is facially misleading.

Who Is Most at Risk: High-Risk Supplement Categories

The FDA has been tracking undeclared pharmaceutical ingredients in supplements for over a decade. The data is sobering.

According to FDA's research and enforcement history, three supplement categories account for the vast majority of undeclared drug ingredient violations:

Category	Common Hidden Ingredient	FDA Drug Class
Sexual Enhancement	Sildenafil, Tadalafil, Vardenafil	PDE5 Inhibitors (Rx only)
Weight Loss	Sibutramine, Phenolphthalein	Controlled/Withdrawn Drugs
Muscle Building	Anabolic Steroids, SARMs	Controlled Substances / Unapproved Drugs
Energy/Cognitive	Adrafinil, Oxiracetam	Unapproved New Drugs
Pain Relief	NSAIDs (prescription-strength)	Rx or Withdrawn APIs

Between 2007 and 2023, the FDA identified more than 1,000 dietary supplements adulterated with undeclared drug ingredients. Sexual enhancement products consistently top the list. The Boner Bears recall is not an anomaly — it is part of a well-documented enforcement pattern that shows no signs of slowing.

Citation hook: FDA has identified undeclared pharmaceutical ingredients — including sildenafil, tadalafil, and sibutramine — in over 1,000 dietary supplement products since 2007, making adulteration with active drug ingredients one of the most persistent violations in the dietary supplement industry.

The Public Health Stakes: Why Sildenafil Is Particularly Dangerous

Sildenafil is not a benign substance. It is a prescription drug regulated under 21 CFR because it requires medical supervision. When hidden in a consumer product marketed as a supplement:

Patients on nitrates (prescribed for angina, heart failure) face potentially fatal hypotension if they unknowingly consume sildenafil.
Patients with cardiovascular conditions may be contraindicated for PDE5 inhibitors entirely.
Diabetic patients taking certain antifungal medications face dangerous drug-drug interactions.
Consumers have no informed consent — they cannot make an autonomous risk decision about a drug they do not know they are taking.

According to the FDA, at least 49 dietary supplements contained undeclared sildenafil or sildenafil analogs in a single year of testing, representing a systemic supply chain vulnerability — not just individual bad actors.

How Undeclared Drug Ingredients Enter the Supply Chain

In my eight-plus years of working with supplement manufacturers, I have seen this failure occur through several distinct pathways:

1. Adulterated Raw Materials from Suppliers

The most common pathway. A raw material supplier — often overseas — adds a drug ingredient to increase product efficacy without disclosing it. The manufacturer never tests for it, assumes the Certificate of Analysis (COA) is accurate, and releases a finished product that contains a pharmaceutical drug.

2. Intentional Spiking Without Documentation

Some operators knowingly add drug ingredients to make products "work" and drive repeat purchases, gambling that testing won't occur. This is not just a regulatory violation — it crosses into criminal fraud territory under 18 U.S.C. § 1001.

3. Cross-Contamination in Shared Facilities

If a contract manufacturer produces both pharmaceutical and supplement products on shared equipment without adequate cleaning validation, cross-contamination can introduce drug residues.

4. Testing Gaps in Finished Product Release

Even well-intentioned manufacturers fail to test for a broad enough panel of potential adulterants in finished goods, relying solely on supplier COAs.

Compliance Roadmap: What Supplement Manufacturers Must Do Now

If you manufacture or market dietary supplements — especially in sexual enhancement, weight loss, or bodybuilding categories — here is the compliance action plan I implement with clients at Certify Consulting:

Step 1: Audit Your Supplier Qualification Program (Immediate)

Under 21 CFR § 111.70(a), you must establish component specifications and qualify suppliers against them. This means: - Require third-party certificates from accredited labs, not just supplier-generated COAs - Conduct periodic incoming material testing using your own qualified laboratory - Maintain approved supplier lists with documented re-qualification intervals

Step 2: Expand Your Finished Product Testing Panel (30 Days)

Your finished product specification under 21 CFR § 111.70(e) must include identity and purity parameters. For high-risk categories, this means: - Add PDE5 inhibitor screening (sildenafil, tadalafil, vardenafil, and analogs) to your finished product panel - Test 100% of lots until supply chain confidence is established, then reduce frequency based on risk - Use accredited third-party labs with validated methods for pharmaceutical adulterants

Step 3: Implement a Risk-Based Adulterant Testing Protocol (60 Days)

The FDA has published a list of known adulterant targets by product category. Build a testing matrix that maps your product categories to known adulterant risks and schedules testing accordingly.

Step 4: Review Your Labeling for Completeness (30 Days)

Conduct a label audit against 21 CFR § 101.4 and your current formulas. Every ingredient must be declared. If your formula has changed since label approval, the label must be updated before distribution.

Step 5: Establish a Recall Readiness Plan (90 Days)

Under 21 CFR Part 7, you should have a written recall procedure that includes: - Lot traceability from raw material to consumer - Contact lists for distributors and retailers - A designated recall coordinator - Communication templates for FDA and the public

Comparison: Voluntary Recall vs. FDA-Mandated Recall

Lockout Supplements initiated a voluntary recall — which is actually the preferred outcome from a regulatory and reputational standpoint. Here is how voluntary and mandatory recalls compare:

Factor	Voluntary Recall	FDA-Mandated Recall (21 U.S.C. § 350l)
Initiator	Company	FDA orders after company refuses
Regulatory Disposition	Generally favorable	May trigger warning letter or injunction
Criminal Exposure	Lower	Higher — suggests knowledge and resistance
Press Release	Company-drafted, FDA-posted	FDA-drafted, less favorable framing
Follow-Up Inspections	Likely	Likely plus increased scrutiny
Class I Classification	Possible	Likely for drug adulteration
Corrective Action Plan Required	Yes	Yes, with stricter deadlines

The lesson: If you discover a problem before FDA does, report it and recall voluntarily. The difference in legal exposure and agency relationship is substantial. A voluntary recall with a strong corrective action plan can preserve a business. Waiting for FDA to mandate action often does not.

Enforcement Trends: What FDA Is Signaling in 2026

This recall does not exist in a vacuum. In 2025 and into 2026, FDA's Office of Dietary Supplement Programs (ODSP) has signaled increased enforcement priority in three areas:

Sexual enhancement supplements — ongoing testing program targeting PDE5 inhibitor adulteration
Online direct-to-consumer brands — e-commerce supplement sellers with limited retail presence are receiving more scrutiny, not less
Third-party marketplace accountability — FDA has begun exploring accountability frameworks for platforms selling adulterated supplements

Citation hook: FDA's enforcement posture in 2025–2026 reflects a strategic shift toward proactive market sampling of high-risk supplement categories, meaning manufacturers can no longer rely on obscurity or low sales volume as a practical shield from testing and enforcement.

If you sell through Amazon, your own website, or regional retailers — and your product is in a high-risk category — assume FDA has or will test your product. Build your compliance program accordingly.

What Happens After a Recall: The Corrective Action Expectation

A recall is not the end of the regulatory story — it is the beginning of a corrective action cycle. After a Class I or Class II recall for drug adulteration, FDA expects:

Root cause analysis documenting exactly how the drug ingredient entered the product
CAPA (Corrective and Preventive Action) addressing systemic gaps in manufacturing controls
Updated SOPs for component qualification and finished product testing
Re-inspection — FDA may schedule a follow-up inspection within 12 months
Import alerts if raw materials were sourced internationally and the supplier is implicated

Failure to implement adequate corrective actions after a recall can result in a Warning Letter, Consent Decree, or injunctive action — each of which is significantly more disruptive and costly than the recall itself.

For guidance on building a recall-ready compliance infrastructure, review our resources on FDA dietary supplement cGMP compliance and FDA warning letter response strategies.

Working With an FDA Compliance Consultant

The regulatory complexity surrounding dietary supplement manufacturing is not something most in-house teams can navigate alone — especially in high-risk product categories. At Certify Consulting, my team has an unbroken 100% first-time audit pass rate across 200+ clients, built on one principle: we find the compliance gaps before FDA does.

If you manufacture sexual enhancement supplements, weight loss products, or any supplement with ingredients sourced from overseas supply chains, now is the time to conduct a proactive cGMP gap assessment. Waiting for a 483 observation or a recall notice is always more expensive than getting ahead of the problem.

Visit certify.consulting to learn how we can support your supplement compliance program.

FAQ: Undeclared Drug Ingredients in Dietary Supplements

Q: What is the FDA's legal authority to recall a supplement containing undeclared drug ingredients?
A: FDA has authority under 21 U.S.C. § 342 to deem a dietary supplement adulterated when it contains an ingredient that may render it injurious to health. FDA can mandate a recall under 21 U.S.C. § 350l for Class I health hazards, and can pursue injunctive relief and criminal prosecution under 21 U.S.C. § 332 and § 333 for repeated or knowing violations.

Q: If my supplier provided a Certificate of Analysis showing no drug ingredients, am I protected from liability?
A: No. A COA from a supplier does not satisfy your regulatory obligations under 21 CFR Part 111. You are required to independently verify that your components and finished products meet your established specifications. Relying solely on supplier COAs — without your own confirmatory testing — is itself a cGMP violation that FDA will cite during an inspection.

Q: What is the difference between a Class I and Class II recall for a supplement?
A: A Class I recall involves a product that presents a reasonable probability of serious adverse health consequences or death — which typically applies to undeclared prescription drug ingredients like sildenafil. A Class II recall involves a product that may cause temporary adverse health consequences but where serious harm is remote. Drug adulteration in supplements almost always triggers Class I classification.

Q: How quickly must a company act once it discovers an undeclared ingredient in its product?
A: There is no specific statutory deadline for initiating a voluntary recall, but FDA expects prompt action once a safety issue is identified. Delays in initiating a recall after discovery can constitute a violation under 21 U.S.C. § 331 and may be used as evidence in subsequent enforcement actions. Industry best practice is to notify FDA and initiate recall procedures within 24–72 hours of confirmed adulteration.

Q: Can a company continue selling other products while one SKU is under recall?
A: Generally yes, if the recall is limited to a specific product and lot, and if there is no reason to believe other products are similarly affected. However, FDA may request records for related products during a recall investigation, and any systemic manufacturing deficiency discovered during the recall can trigger a broader action. A thorough internal investigation of related products is strongly advisable.

Jared Clark is the principal consultant at Certify Consulting, with 8+ years of FDA regulatory experience across dietary supplements, food manufacturing, and medical devices. He holds credentials as a Registered FDA Regulatory Affairs Consultant (RAC), Certified Food Safety Quality Auditor (CFSQA), and Certified Professional Good Manufacturing Practices (CPGP), among others. Visit certify.consulting for compliance resources and consultation services.